Application of kidney tonifying and asthma relieving decoction in treating asthma

Abstract

The invention relates to the technical field of medicine, in particular to application of kidney tonifying and asthma relieving decoction in treating asthma, and is technically characterized in that according to the scheme, a bronchial asthma kidney qi deficiency syndrome model is established, a pyroptosis path is utilized, and key inflammatory bodies and inflammatory body related cell factors of the pyroptosis are combined, so that the bronchial asthma kidney qi deficiency syndrome model is established. According to the invention, the mechanism of the kidney-tonifying and asthma-relieving decoction for improving asthma symptoms and intervening the development of the disease course is deeply researched, the mechanism of the kidney-tonifying and asthma-relieving decoction for regulating and controlling the pyroptosis of asthma cells and inhibiting the expression of T cell NLRP3, Caspase 1, Gasdermin family and IL-1beta through an STAT6 / GATA-3 pathway so as to improve the airway inflammation of asthma is provided, and the research on the influence of the kidney-tonifying and asthma-relieving decoction on the pyroptosis signal pathway is developed. The invention can provide a scientific basis for the application of the kidney-tonifying and asthma-relieving decoction to the treatment of asthma, further research the effective target of the kidney-tonifying and asthma-relieving decoction on the molecular level and the essential material basis of the kidney qi deficiency syndrome, and provide a theoretical basis and a new thought for revealing the pathogenesis of asthma and research on the essence of the syndrome.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and more particularly, to the application of Yishen Chuanning Decoction in the treatment of asthma. Background Art

[0002] The kidney qi deficiency syndrome of bronchial asthma is a type of syndrome classification of bronchial asthma in traditional Chinese medicine. Its symptoms in terms of respiration are as follows: wheezing for a long time, shortness of breath, more exhalation than inhalation, and worse wheezing with movement, and the qi cannot continue. Patients often feel dyspnea, especially the symptoms worsen after activity, and the exhalation time is significantly prolonged. The etiology and pathogenesis are that the kidney qi deficiency syndrome of bronchial asthma is mostly due to long-term illness and weakness of the body, insufficient kidney qi, abnormal reception and control, inability to assist the lung in receiving qi, resulting in loss of qi reception and control, rising upward from the lung, more exhalation than inhalation, and reverse qi rushing upward to cause wheezing. The kidney is the root of qi and is responsible for the reception and control of qi. When kidney qi is deficient, there is no power of reception and control, and qi floats upward, leading to wheezing. The common treatment methods are usually as follows:

[0003] 1. Traditional Chinese medicine treatment: The commonly used prescriptions are to select and modify Renshen Hutao Decoction and Jinkui Shenqi Pills. In Renshen Hutao Decoction, ginseng greatly tonifies the primordial qi, and walnut warms the kidney yang, receives qi and relieves wheezing. When the two are combined, the kidney qi is replenished, the reception and control are in order, and the wheezing is relieved. Jinkui Shenqi Pills can warm the kidney yang, transform qi and promote diuresis, and improve symptoms such as wheezing caused by kidney qi deficiency. Syndrome differentiation and modification: If it is partial to yin deficiency, Liuwei Dihuang Pills can be used to nourish the kidney yin; if there is concurrent lung qi deficiency, herbs such as astragalus and codonopsis pilosula that tonify the lung qi can be added.

[0004] 2. Acupuncture treatment: Select acupoints such as Feishu, Gaohuang, Qihai, Shenshu, Zusanli, Taiyuan, and Taixi, and use the reinforcing method with filiform needles, and moxibustion can be used as appropriate. These acupoints can regulate the functions of the lung and kidney, enhance the vital qi of the body, and improve the symptoms of kidney qi deficiency.

[0005] 3. Other therapies: During the remission period, moxibustion with wheat grains is used. Select acupoints Dazhui, Fengmen, Feishu, and Tanzhong, and moxibust 3 - 5 cones at each acupoint each time, once every 10 days, and 3 times is a course of treatment. It is best used during the dog days of summer.

[0006] Yishen Chuanning Decoction is a traditional Chinese medicine prescription for treating kidney deficiency type asthma, and has the effects of tonifying the kidney and receiving qi, resolving phlegm and relieving wheezing. However, there has been no report on the mechanism of Yishen Chuanning Decoction in improving asthma symptoms and intervening in the course of the disease. Therefore, the purpose of this application is to provide the application of Yishen Chuanning Decoction in the treatment of asthma to solve the above problems. Summary of the Invention

[0007] The purpose of the present invention is to solve the technical problems raised in the above background art, and provide the application of Yishen Chuanning Decoction in the treatment of asthma.

[0008] The above object of the present invention is achieved as follows:

[0009] On the one hand, the solution of the present invention provides the application of Yishen Chuanning Decoction in the preparation of drugs for treating asthma.

[0010] Furthermore, the Yishen Chuanning Decoction regulates pyroptosis of asthma cells through the STAT6 / GATA-3 pathway, inhibits the expression of NLRP3, Caspase 1, Gasdermin family, and IL-1β in T cells, thereby improving airway inflammation in asthma.

[0011] Furthermore, the concentration of the Yishen Chuanning Decoction is 10% - 30%.

[0012] Furthermore, the concentration of the Yishen Chuanning Decoction is 20%.

[0013] On the other hand, the solution of the present invention provides a method for constructing a rat model combining disease and syndrome of kidney qi deficiency in asthma, including the following steps:

[0014] Use the OVA sensitization method combined with multi-factor compound methods such as aerosol inhalation and panic stress, suspension stress, and swimming fatigue for modeling. On the 1st and 8th days of the experiment, 1 mL of a physiological saline mixture containing 100 mg of ovalbumin and 100 mg of aluminum hydroxide dry powder was injected into the abdominal cavity of the rats to sensitize them, and they were reserved for use after 2 weeks. Starting from the 15th day, the above-mentioned modeled rats were placed in a glass cover with a size of 65 cm × 45 cm × 45 cm in batches, and ultrasonic aerosol inhalation was performed for 30 min with a 1% concentration of ovalbumin solution (OVA dissolved in sterilized 0.9% sodium chloride injection, the preparation ratio is 10 mg:1 ml, shaken and mixed evenly) to induce asthma, once a day, continuously until sacrificed. Every morning at the same time period, the rats were placed in a quiet room to give panic stimuli, play the recording of cat meows, lift the rats by the tail and suspend them, and use a plum blossom needle to prick the back of the rats forcefully (20 - 25 times / min), 15 min each time. Every afternoon at the same time period, the rats were made to swim. First, ice bags were placed in a water tank with a water depth of 50 cm, and the water temperature was measured with a thermometer. The standard water temperature was 16°C. The rats were placed in the water tank in batches until they were exhausted. The observation standard was that the rat's nose tip was submerged in the water surface for more than 10 s. After that, the rat hair was dried, and the rats were placed in an environment of 26°C for 30 min and then put into the cage. Once a day, for a total of 2 weeks.

[0015] On the other hand, the solution of the present invention also provides the application of the rat model combining disease and syndrome of kidney qi deficiency in asthma obtained by the method for constructing a rat model combining disease and syndrome of kidney qi deficiency in asthma in studying the mechanism of Yishen Chuanning Decoction in treating asthma.

[0016] The difficulty and significance of the present invention in solving technical problems are as follows:

[0017] Based on the etiology, pathogenesis, treatment principles, overall concept, and syndrome differentiation and treatment of traditional Chinese medicine (TCM), and considering the important role of the STAT6 / GATA-3 pathway in immune-inflammatory diseases, this invention studies the mechanism by which specific transcription factors and cytokines related to the STAT6 / GATA-3 pathway affect the pyroptosis state of asthma cells from a new perspective of pyroptosis, showing theoretical innovation. Moreover, under the guidance of TCM theory, the inventors of this application established an animal model combining disease and syndrome of kidney qi deficiency in asthma, which is more in line with TCM theory than the current simple asthma model and is more conducive to exploring the mechanism of Yishen Chuanning Decoction in treating asthma based on the correspondence between formula and syndrome in the kidney qi deficiency syndrome model of asthma, providing new ideas for the diagnosis and treatment of various diseases.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] 1. The solution of the present invention addresses the mechanism of regulating pyroptosis in the kidney qi deficiency syndrome of asthma based on the STAT6 / GATA-3 pathway, and conducts research on the mechanism of traditional Chinese medicine in regulating immune imbalance.

[0020] 2. The solution of the present invention is based on research techniques and methods such as molecular biology and immunology, studies the complex relationship between the macroscopic phenotypes of syndromes and microscopic biomolecules, and reveals part of the scientific connotation of the essence of the kidney qi deficiency syndrome at the molecular level.

[0021] 3. The solution of the present invention provides the application of Yishen Chuanning Decoction in the treatment of asthma, and comprehensively explains the possible mechanism of the kidney qi deficiency syndrome in bronchial asthma and the curative effect mechanism of Yishen Chuanning Decoction, providing a more favorable basis for guiding clinical medication. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 shows the morphological conditions of the lung tissues of rats in each group in the embodiment of the present invention (scale: 50 μm);

[0023] Figure 2 shows the comparison of the mRNA expression levels of NLRP3, IL-33, GATA-3, STAT6, IFN-γ, and GSDMD in the lung tissues of rats in each group in the embodiment of the present invention (mean±SD, n = 9);

[0024] Figure 3 shows the comparison of the protein levels of NLRP3, IL-33, GATA-3, STAT6, IFN-γ, and GSDMD in the lung tissues of rats in each group in the embodiment of the present invention (mean±SD, n = 3);

[0025] Figure 4 shows the detection of cell viability by the CCK-8 method in the embodiment of the present invention (**P<0.01 vs. the model group; ##P<0.01 vs. the model + traditional Chinese medicine group);

[0026] Figure 5LDH release rates in each group in the embodiments of the present invention (**P<0.01 vs. model group; ##P<0.01 vs. model + traditional Chinese medicine group);

[0027] Figure 6 Observation of autophagosome changes by electron microscopy in the embodiments of the present invention;

[0028] Figure 7 Detection of autophagic flux by mRFP-GFP-LC3 adenovirus in the embodiments of the present invention;

[0029] Figure 8 Change in the number of fluorescent dots in the embodiments of the present invention;

[0030] Figure 9 Observation of fluorescent expression of apoptotic cells by Tunel staining in the embodiments of the present invention;

[0031] Figure 10 Observation of cell apoptosis rate by Tunel staining in the embodiments of the present invention (**P<0.01 vs. model group; ##P<0.01 vs. model + traditional Chinese medicine group);

[0032] Figure 11 Detection of fluorescent expression of caspase1 by immunofluorescence staining in the embodiments of the present invention;

[0033] Figure 12 Detection of fluorescence intensity of Caspase-1 protein by immunofluorescence method in the embodiments of the present invention (**P<0.01 vs. model group; ##P<0.01 vs. model + traditional Chinese medicine group);

[0034] Figure 13 Detection of the expression of autophagy- and pyroptosis-related proteins by Western blot in the embodiments of the present invention (**P<0.01 vs. model group; ##P<0.01 vs. model + traditional Chinese medicine group). Detailed implementation manners

[0035] In order to make the objectives, technical solutions and advantages of the present invention clearer and more understandable, the following further elaborates on the present invention in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0036] The following describes the implementation of the present invention in detail with specific embodiments.

[0037] Refer to Figures 1-13 As shown below, the following are the preferred embodiments provided by the present invention.

[0038] Example: The solution of the present invention provides the application of Yishen Chuanning Decoction in the preparation of drugs for treating asthma, and provides a method for constructing a rat model of the combination of asthma and kidney qi deficiency syndrome and its application in studying the mechanism of Yishen Chuanning Decoction in treating asthma.

[0039] The following are the specific implementations of the solution of the present invention:

[0040] I. Animal experiment

[0041] Method: Forty rats were randomly divided into a normal group, a kidney asthma group, a traditional Chinese medicine group, a western medicine group, and a traditional Chinese medicine + western medicine group, with 8 rats in each group. A model of bronchial asthma with kidney qi deficiency syndrome was established by using a multi-factor composite method to simulate traditional Chinese medicine etiology and combining ovalbumin sensitization and aerosol inhalation challenge. The pathological changes of bronchi in the lung tissue of rats were observed by hematoxylin-eosin (HE) staining; the levels of inflammatory cytokines IL-1β, IL-4, IL-18, IL-17A, CORT, T4, and T in the peripheral blood of rats were detected by enzyme-linked immunosorbent assay (ELISA); the mRNA expressions of NLRP3, IL-33, GATA-3, STAT6, IFN-γ, and GSDMD in the lung tissue were detected by RT-qPCR; the protein expressions of IL-33, GATA-3, GSDMD, IFN-γ, NLRP3, and STAT6 in the lung tissue were detected by western blotting (WB). Comparing the results with those of the kidney asthma group, the levels of IL-1β, IL-18, IL-17A, and IL-4 in the peripheral blood of the normal group, the western medicine group, the traditional Chinese medicine group, and the traditional Chinese medicine + western medicine group decreased, while the levels of CORT, T4, and T increased (P < 0.05). The mRNA and protein expression levels of NLRP3, IL-33, GATA-3, STAT6, and GSDMD in the lung tissue decreased, and the expression level of IFN-γ increased (P < 0.05), showing the same trend. Conclusion: Yishen Chuanning Decoction can reduce pro-inflammatory factors and increase anti-inflammatory factors, testosterone, and thyroxine, thereby inhibiting the inflammatory response of bronchial asthma.

[0042] The results of the animal experiment are as follows:

[0043] 1. Morphological conditions of the lung tissue of rats in each group

[0044] In the normal group, the structures of bronchi and alveolar walls in the lung tissue were clear and intact. In the kidney asthma group, the bronchial lumen was narrowed, the mucosal epithelial cells were exfoliated and necrotic, and a large number of inflammatory cells infiltrated around the bronchi. Compared with the kidney asthma group, each treatment group had obvious improvements, with less adhesion and necrosis of bronchial mucosal epithelium and a small amount of inflammatory cell infiltration. Among them, the traditional Chinese medicine + western medicine group had the most obvious improvement, as shown in Figure 1 shown.

[0045] 2. Comparison of the levels of IL-1β, IL-18, IL-17A, CORT, T4, and T in the peripheral blood of rats in each group

[0046] Compared with the kidney asthma group, the levels of IL-1β, IL-18, IL-17A, and IL-4 in the peripheral blood of the normal group, western medicine group, traditional Chinese medicine group, and traditional Chinese medicine + western medicine group decreased, while the levels of CORT, T4, and T increased (P < 0.05). Compared with the traditional Chinese medicine group, the levels of IL-1β, IL-18, IL-17A, and IL-4 in the peripheral blood of the normal group and traditional Chinese medicine + western medicine group decreased (P < 0.05), the levels of CORT, T4, and T increased (P < 0.05), and there was no significant difference in the western medicine group (P > 0.05), as shown in Table 1.

[0047] Table 1 Comparison of the levels of IL-1β, IL-4, IL-18, IL-17A, CORT, T4, and T in the peripheral blood of rats in each group (mean ± SD, n = 8)

[0048]

[0049] Note: ** P < 0.01 vs the model group; ## P < 0.01 vs the traditional Chinese medicine group.

[0050] 3. Comparison of the mRNA expression levels of NLRP3, IL-33, GATA-3, STAT6, IFN-γ, and GSDMD in the lung tissues of rats in each group

[0051] Compared with the kidney asthma group, the mRNA expression levels of NLRP3, IL-33, GATA-3, STAT6, and GSDMD in the lung tissues of the normal group, western medicine group, traditional Chinese medicine group, and traditional Chinese medicine + western medicine group decreased, while the expression level of IFN-γ increased (P < 0.05). Compared with the traditional Chinese medicine group, the mRNA expression levels of NLRP3, IL-33, GATA-3, STAT6, and GSDMD in the lung tissues of the normal group and traditional Chinese medicine + western medicine group decreased (P < 0.05), the expression level of IFN-γ increased (P < 0.05), and there was no significant difference in the western medicine group (P > 0.05), as shown in Figure 2 .

[0052] 4. Comparison of the protein expressions of NLRP3, IL-33, GATA-3, STAT6, IFN-γ, and GSDMD in the lung tissues of rats in each group

[0053] Compared with the kidney asthma group, the protein expression levels of NLRP3, IL-33, GATA-3, STAT6, and GSDMD in the lung tissues of the normal group, western medicine group, traditional Chinese medicine group, and traditional Chinese medicine + western medicine group decreased, while the expression level of IFN-γ increased (P < 0.05). Compared with the traditional Chinese medicine group, the protein expression levels of NLRP3, IL-33, GATA-3, STAT6, and GSDMD in the lung tissues of the normal group and traditional Chinese medicine + western medicine group decreased (P < 0.05), the expression level of IFN-γ increased (P < 0.05), and there was no significant difference in the western medicine group (P > 0.05), as shown inFigure 3 。

[0054] II. Cell experiments:

[0055] Methods: The experiments were divided into 5 groups: normal group, model group, traditional Chinese medicine group, dexamethasone group, and traditional Chinese medicine + dexamethasone group. CCK8 was used to detect cell proliferation viability to screen the optimal dose of Yishen Chuanning Decoction. LDH was used to observe the cell damage condition. Transmission electron microscopy was used to observe the changes of autophagosomes in cells. Autophagy dual-labeled adenovirus experiments were used to observe the changes of autophagic flux. Tunel staining was used to observe the cell apoptosis rate. Immunofluorescence was used to detect the expression of Caspase-1. Western blot was used to detect the protein expressions of IL-1β, IL-18, Caspase-1, Caspase-3, Beclin-1, and Atg-5.

[0056] Results: The screening results of the CCK8 experiment showed that the best effect was achieved when the concentration of the freeze-dried powder of Yishen Chuanning Decoction was 20% and cultured for 48 h. Electron microscopy results found that the cells in the normal group had normal morphology, intact cell membranes, clear mitochondrial cristae structures, and many autophagosomes. The mitochondria in the model group cells were normal, and there were fewer autophagosomes. In the model + traditional Chinese medicine group, the mitochondria in the cells were shrunken, the mitochondrial cristae were reduced, and the membrane density increased. The number of autophagosomes was increased compared with the model group. In the model + dexamethasone group, the mitochondria in the cells were swollen, and the mitochondrial cristae were reduced. The autophagosomes were similar to those in the model + traditional Chinese medicine group. In the model + traditional Chinese medicine + dexamethasone group, the mitochondria in the cells were swollen, the mitochondrial cristae were reduced, and the number of autophagosomes was reduced compared with the model + traditional Chinese medicine group. The results of the autophagy dual-labeled adenovirus experiment found that compared with the normal group, the model + traditional Chinese medicine group, the model + dexamethasone group, and the model + traditional Chinese medicine + dexamethasone group, the yellow spots in the model group were significantly fewer, and the yellow spots were fewer than the red spots, that is, there were fewer autophagosomes and autolysosomes; compared with the normal group and the model + traditional Chinese medicine + dexamethasone group, the red and yellow spots in the model + traditional Chinese medicine group were reduced, that is, the autolysosomes and autophagosomes were reduced. Compared with the model group, the LDH leakage rate, IL-18, IL-1β, and Caspase-1 in the normal group, the model + traditional Chinese medicine group, the model + dexamethasone group, and the model + traditional Chinese medicine + dexamethasone group were significantly reduced (P < 0.01), and the cell apoptosis rate, Atg-5, Beclin-1, and Caspase-3 were significantly increased (P < 0.01); compared with the model + traditional Chinese medicine group, the LDH leakage rate in the normal group and the model + traditional Chinese medicine + dexamethasone group was significantly reduced (P < 0.01), and the cell apoptosis rate, Atg-5, Beclin-1, and Caspase-3 were significantly increased (P < 0.01). Conclusion: Yishen Chuanning Decoction can inhibit the survival rate of human bronchial airway epithelial-like cells, reduce autophagy and pyroptosis of cells, and promote cell apoptosis.

[0057] The results of the cell experiments are as follows:

[0058] 1. Effects of Yishen Chuanning Decoction on cell proliferation

[0059] Screen the freeze-dried culture solution of Yishen Chuanning Decoction at 5%, 10%, 20%, and 30%. Compared with the traditional Chinese medicine group, the cell inhibition rate increased (P < 0.01) after adding it; compared with adding 5% Yishen Chuanning Decoction, the cell survival rate decreased after adding 10%, 20%, and 30% Yishen Chuanning Decoction (P < 0.01), and there was no significant difference in the cell inhibition rate between adding 20% and 30% Yishen Chuanning Decoction (P > 0.05). Therefore, the optimal concentration of Yishen Chuanning Decoction was selected as 20%; compared with 0 h, 12 h, and 24 h, the cell inhibition rate increased at 48 h and 72 h (P < 0.01), and there was no significant difference in cell viability between 48 h and 72 h (P > 0.01). Therefore, the optimal action time of Yishen Chuanning Decoction was 48 h, as shown in Figure 4 .

[0060] 2. Effects of Yishen Chuanning Decoction on the degree of cell damage

[0061] Compared with the model group, the LDH leakage rate in the normal group, model + traditional Chinese medicine group, model + dexamethasone group, and model + traditional Chinese medicine + dexamethasone group was significantly reduced (P < 0.01). Compared with the normal group, model + traditional Chinese medicine + dexamethasone group, and model + traditional Chinese medicine group, the LDH leakage rate in the normal group was significantly reduced (P < 0.01), as shown in Figure 5 .

[0062] 3. Effects of Yishen Chuanning Decoction on cell autophagy

[0063] In the normal group, the cell morphology was normal, the cell membrane was intact, the mitochondrial cristae structure was clear, and there were many autophagosomes. In the model group, the mitochondria in the cells were normal, and there were fewer autophagosomes. In the model + traditional Chinese medicine group, the mitochondria in the cells were shrunk, the mitochondrial cristae were reduced, the membrane density increased, and the number of autophagosomes was increased compared with the model group. In the model + dexamethasone group, the mitochondria in the cells were swollen, the mitochondrial cristae were reduced, and the autophagosomes were similar to those in the model + traditional Chinese medicine group. In the model + traditional Chinese medicine + dexamethasone group, the mitochondria in the cells were swollen, the mitochondrial cristae were reduced, and the number of autophagosomes was reduced compared with the model + traditional Chinese medicine group, as shown in Figure 6 .

[0064] Compared with the normal group, model + traditional Chinese medicine group, model + dexamethasone group, and model + traditional Chinese medicine + dexamethasone group, the yellow spots in the model group were significantly fewer, and the yellow spots were fewer than the red spots, that is, there were fewer autophagosomes and autolysosomes; compared with the normal group and model + traditional Chinese medicine + dexamethasone group, the red spots and yellow spots in the model + traditional Chinese medicine group were reduced, that is, the autolysosomes and autophagosomes were reduced, as shown in Figure 7 、 Figure 8 shown

[0065] 4. Effects of Yishen Chuanning Decoction on cell apoptosis

[0066] Compared with the normal group, the model + traditional Chinese medicine group, the model + dexamethasone group, and the model + traditional Chinese medicine + dexamethasone group, the apoptosis rate in the model group was significantly increased (P < 0.01); compared with the normal group and the model + traditional Chinese medicine + dexamethasone group, the apoptosis rate in the model + traditional Chinese medicine group was significantly increased (P < 0.01), as shown in Figure 9 、 Figure 10 shown.

[0067] 5. Effects of Yishen Chuanning Decoction on pyroptosis

[0068] Compared with the normal group, the model + traditional Chinese medicine group, the model + dexamethasone group, and the model + traditional Chinese medicine + dexamethasone group, caspase1 was significantly decreased in the model group (P < 0.01); compared with the normal group and the model + traditional Chinese medicine + dexamethasone group, caspase1 was significantly decreased in the model + traditional Chinese medicine group (P < 0.01), as shown in Figure 11 、 Figure 12 shown.

[0069] 6. Detection of expressions of autophagy- and pyroptosis-related proteins by Western blot

[0070] Compared with the model group, IL-18, IL-1β, and Caspase-1 were significantly decreased, while Atg-5, Beclin-1, and Caspase-3 were significantly increased in the normal group, the model + traditional Chinese medicine group, the model + dexamethasone group, and the model + traditional Chinese medicine + dexamethasone group (P < 0.01). Compared with the model + traditional Chinese medicine group, IL-18, IL-1β, and Caspase-1 were significantly decreased, while Atg-5, Beclin-1, and Caspase-3 were significantly increased in the normal group and the model + traditional Chinese medicine + dexamethasone group (P < 0.01), as shown in Figure 13 shown.

[0071] The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, and improvements made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

Claims

1. Application of Yishenchuanning Decoction in the preparation of medicines for the treatment of asthma.

2. The use according to claim 1, characterized in that: The Yishenchuanning Decoction regulates asthma cell pyroptosis through the STAT6 / GATA-3 pathway, inhibits the expression of T cell NLRP3, Caspase 1, Gasdermin family, and IL-1β, thereby improving asthma airway inflammation.

3. The use according to claim 1, characterized in that: The concentration of the Yishenchuanning decoction is 10% to 30%.

4. The use according to claim 3, characterized in that: The concentration of the Yishenchuanning decoction is 20%.

5. A method for constructing a rat model of asthma with kidney-qi deficiency syndrome, characterized in that: The following steps are involved: The rat model of asthma with kidney-qi deficiency syndrome was established by OVA sensitization combined with aerosol stimulation and multi-factor composite method of shock stress, suspension stress and swimming fatigue. On the first and eighth days, 1 mL of a physiological saline mixture containing 100 mg of ovalbumin and 100 mg of aluminum hydroxide powder was injected into the abdominal cavity of the rats to sensitize them, and they were kept ready for use after 2 weeks. Starting from the 15th day, the rats were placed in batches in a glass cover of 65 cm × 45 cm × 45 cm and subjected to ultrasonic atomization inhalation of 1% ovalbumin solution for 30 min to stimulate asthma, once a day for a continuous period. Every morning at the same time, the rats were placed in a quiet room to give them a startle stimulus, and a recording of a cat's cry was played. The rats were suspended by their tails and their backs were vigorously pricked with plum blossom needles for 15 minutes each time. Let the rats swim at the same time every afternoon. First, put ice packs in a 50cm deep water tank and test the water temperature with a thermometer. 16℃ is the standard water temperature. Put the rats in batches into the water tank and let them swim until they are exhausted. The observation standard is that the tip of the rat's nose is submerged in the water for more than 10 seconds. After the end, wipe the mouse's fur dry, place it in a 26°C environment for 30 minutes, and then put it back into the cage; do this once a day for 2 weeks.

6. Use of the asthma kidney-qi deficiency syndrome combined with disease syndrome rat model obtained by the method for constructing an asthma kidney-qi deficiency syndrome combined with disease syndrome according to claim 5 in studying the mechanism of Yishen Chuanning Decoction in treating asthma.

Images